Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial
Cameron, David, Morden, James P, Canney, Peter, Velikova, Galina, Coleman, Robert, Bartlett, John, Agrawal, Rajiv, Banerji, Jane, Bertelli, Gianfilippo, Bloomfield, David, Brunt, A Murray, Earl, HelenLanguage:
english
Journal:
The Lancet Oncology
DOI:
10.1016/s1470-2045(17)30404-7
Date:
June, 2017
File:
PDF, 595 KB
english, 2017